<div id="readability-page-1"><article><p>NEW YORK, Dec.  26, 2025  (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).</p> <p>The Common Shares were sold at a price of USD$7.50 per Common Share.</p> <p>Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis).</p> <p>Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.</p> <p>This press release has been issued in order to comply with applicable securities legislation.</p> <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0"/> <br/><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png"/><br/><pre>For further information: Anthony J. Buffalano IIISouthpoint Capital Advisors LP1114 Avenue of the Americas, 22nd FloorNew York, NY 10036Phone: (212) 692-6356</pre></article></div>

FENC

<p>Southpoint Capital Advisors LP announced the disposal of 1,000,000 common shares of Fennec Pharmaceuticals Inc. at USD$7.50 per share, reducing its ownership to 8%. The sale was for investment purposes, and Southpoint may adjust its holdings based on market conditions.</p>

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) | FENC Stock News